Cascara Formula Capsule
Natural health product licensed in Canada
- Licence holder
- BioV Pharma Inc.
- NPN or DIN-HM
- 80069921
- Status
- Inactive licence
- Licence date
- 3 June 2016
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Officinale
If this product were sold in France
- Conditions légales
Frangula purshiana Cooper: L'étiquetage doit comporter un avertissement déconseillant l'emploi aux enfants de moins de 12 ans, aux femmes enceintes et allaitantes ainsi qu'une mention déconseillant l'usage prolongé.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Aloe vera (L.) Burm. f.: L'étiquetage doit comporter un avertissement déconseillant l'emploi aux enfants de moins de 12 ans, aux femmes enceintes et allaitantes et une mention déconseillant l'usage prolongé
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Foeniculum vulgare Mill.: La portion journalière recommandée ne doit pas conduire à une ingestion d'estragole supérieure à 0,05 mg/kg de poids corporel pour les enfants de moins de 12 ans.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Frangula purshiana Source : Écorce âgée | 100 milligramme | Not calculated |
| Plantago arenaria Source : Enveloppe | 100 milligramme | Not calculated |
| Irvingia gabonensis Source : Graine(s) Extract : Matériel brut sec Extraction ratio : 10:1 Dry plant equivalent : 1,000 milligramme | 100 milligramme | Not calculated |
| Extrait de fève de café vert Source : New material Extract : Matériel brut sec Extraction ratio : 4:1 Dry plant equivalent : 400 milligramme Potency : 50 Pour cent Chlorogenic acids | 100 milligramme | Not calculated |
| Aloe vera Source : Latex | 0.5 milligramme | Not calculated |
| Hippophae rhamnoides Source : Écorce (tige) | 0.5 milligramme | Not calculated |
| Foeniculum vulgare subsp. vulgare var. vulgare Source : Graine(s) | 0.5 milligramme | Not calculated |
Non-medicinal ingredients
Gélatine, Dioxyde de silicium, Maltodextrine, Stéarate de magnésium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 1 Capsule | minimum: 1 Tous les jours ; maximum: 2 Tous les jours |
Uses authorised in Canada
stimulant laxative. Could be a complement to a healthy lifestyle that incorporates a calorie-reduced diet and regular physical activity for individuals involved in a weight management program. Helps maintain healthy blood pressure levels. Provides antioxidants.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
Consult a health care practitioner prior to use.
- Contre-indications
Do not use if you are pregnant or breastfeeding. Do not use if you have abnormal constrictions of the gastrointestinal tract, potential or existing intestinal blockage, atonic bowel, appendicitis, inflammatory colon disease such as Crohn's disease or ulcerative colitis, abdominal pain of unknown origin, undiagnosed rectal bleeding, severe dehydration with depleted water or electrolytes or diarrhoea. Do not use if you are experiencing a sudden change in bowel habits that has persisted for more than 2 weeks, undiagnosed rectal bleeding, or failure to defaecate following the use of another laxative product. Do not use if you have diabetes mellitus in which blood sugar is difficult to regulate. Do not use if you have difficulty swallowing.
- Effets indésirables connus
Hypersensitivity, such as allergy, has been known to occur following inhaled and/or ingested psyllium; in which case, discontinue use. May cause temporary gas bloating. If you experience symptoms of hypoglycaemia including feelings of anxiety, dizziness, tremor, sweating, nausea or headache, discontinue use.
Source
Official Health Canada record, licence 80069921
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.